NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S.
As part of the agreement, NAMSA will take ownership of WuXi’s facilities in Minnesota and Georgia. WuXi has a broad portfolio of R&D and manufacturing services for pharmaceutical and life science companies.
“We are extremely pleased to announce our agreement with WuXi AppTec, as it enables us to expand our portfolio of clinical research and testing solutions for clients,” NAMSA CEO André-Michel Ballester said in a news release. “NAMSA and WuXi AppTec’s Medical Device Testing Operations have different areas of expertise but serve the same client base and will enhance the client experience by combining capabilities. Together, we look forward to accelerating MedTech innovation and helping Sponsors deliver life-saving medical technology throughout the world.”
NAMSA’s outsourcing and in-house services allow medtech companies to reduce the risk of regulatory and clinical evidence requirements, according to the company.
The second WuXi sale in recent weeks
This is WuXi’s second facility sale in 2025. On Jan. 6, Merck acquired the company’s vaccine manufacturing facility in Ireland.
Both acquisitions precede potential U.S. legislation that would limit Chinese biotech companies like WuXi, Reuters reports.
According to a recent report, the recently passed Biosecure Act would ban federal contracts with targeted firms and their business partners.
WuXi was specifically named in the legislation, which passed in the U.S. House of Representatives. It needs to pass through the U.S. Senate before becoming a law.
